

WEST**Freeform Search**

Database:
US Patents Full-Text Database ▲
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins ▼

Term:
human near4 ilk ▲
▼

Display: 20 **Documents in Display Format:** - **Starting with Number** 1

Generate: ☐ Hit List ☒ Hit Count ☐ Side by Side ☐ Image

[Search](#)[Clear](#)[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)

Search History

DATE: Wednesday, May 28, 2003 [Printable Copy](#) [Create Case](#)

Set Name Query
 side by side

Hit Count Set Name
 result set

DB=USPT,PGPB; PLUR=YES; OP=AND

L6	human near4 ilk	13	L6
L5	L4 and l3	0	L5
L4	6013782.pn.	1	L4
L3	human near3 integrin-link\$ adj kinase	8	L3
L2	L1 near6 (dna or cdna or polynucleotide or nucleic adj acid or nucleotide)	2	L2
L1	human near3 integrin-linked adj kinase	8	L1

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 2 of 2 returned.**

☐ 1. 20020107216. 08 Aug 01. 08 Aug 02. Integrin-linked kinase and its use. Dedhar, Shoukat, et al. 514/44; 435/194 435/455 536/23.2 A61K048/00 C07H021/04 C12N009/12 C12N015/87.

☒ 2. 6177273. 26 Oct 99; 23 Jan 01. Antisense modulation of integrin-linked kinase expression. Bennett; C. Frank, et al. 435/375; 435/377 435/455 435/6 514/44 536/23.1 536/24.1 536/24.5. C07H021/04 A61K048/00 C12N015/09 C12Q001/68.

[Generate Collection](#)[Print](#)

Terms	Documents
L1 near6 (dna or cdna or polynucleotide or nucleic adj acid or nucleotide)	2



[Previous Page](#)[Next Page](#)

Generate Collection

Print

Search Results - Record(s) 1 through 13 of 13 returned.

- ☐ 1. 20030060453. 15 Feb 02. 27 Mar 03. Pyrazole compounds. Zhang, Zaihui, et al. 514/94; 514/150 534/727 534/769 A61K031/675 A61K031/655.
- ☐ 2. 20030013640. 04 Jun 02. 16 Jan 03. Integrin linked kinase modulation of leukocyte trafficking. Kojic, Ljiljana, et al. 514/2; A61K038/00.
- ☐ 3. 20020155179. 30 Nov 01. 24 Oct 02. Treatment of inflammatory diseases including psoriasis. Dedhar, Shoukat, et al. 424/725.1; 514/223.8 514/251 514/263.37 514/575 514/9 604/20 A61K038/13 A61K031/525 A61N001/30 A61K031/522.
- ☐ 4. 20020122801. 23 Apr 01. 05 Sep 02. Integrin-linked kinase and its uses. Dedhar, Shoukat, et al. 424/146.1; 514/44 514/453 530/388.26 A61K048/00 A61K039/395 A61K031/353 C07K016/40.
- ☐ 5. 20020107216. 08 Aug 01. 08 Aug 02. Integrin-linked kinase and its use. Dedhar, Shoukat, et al. 514/44; 435/194 435/455 536/23.2 A61K048/00 C07H021/04 C12N009/12 C12N015/87.
- ☐ 6. 6500938. 30 Jan 98; 31 Dec 02. Composition for the detection of signaling pathway gene expression. Au-Young; Janice, et al. 536/23.1; 422/50 422/68.1 435/6 436/501 536/24.1 536/24.3 536/24.31 536/24.32 536/24.33. C07H021/00 C07H021/04 C12Q001/68.
- ☐ 7. 6369205. 09 May 00; 09 Apr 02. Integrin-linked kinase and its uses. Dedhar; Shoukat, et al. 530/388.26; 424/139.1 424/142.1 530/387.1 530/388.1 530/388.15. C07K016/00 C12P021/08 A61K039/395.
- 09/12-25
☒ 8. 6338958. 03 Sep 99; 15 Jan 02. Integrin-linked kinase and its uses. Dedhar; Shoukat, et al. 435/194; 435/15 435/4 530/350. C12N009/12 C12Q001/00 C12Q001/48 C07K001/00.
- ☐ 9. 6335170. 22 Feb 00; 01 Jan 02. Gene expression in bladder tumors. Orntoft; Torben F.. 435/6; 435/91.1 435/91.2 536/23.1 536/24.3 536/24.31 536/24.33. C12Q001/68 C12P019/34 C07H021/02.
- ☐ 10. 6331396. 23 Sep 99; 18 Dec 01. Arrays for identifying agents which mimic or inhibit the activity of interferons. Silverman; Robert H., et al. 435/6; 435/287.2 536/23.1 536/23.52 536/24.3 536/24.31. C12Q001/68 C12M001/36 C07H021/04.
- ☐ 11. 6177273. 26 Oct 99; 23 Jan 01. Antisense modulation of integrin-linked kinase expression. Bennett; C. Frank, et al. 435/375; 435/377 435/455 435/6 514/44 536/23.1 536/24.1 536/24.5. C07H021/04 A61K048/00 C12N015/09 C12Q001/68.
- ☒ 12. 6013782. 21 Oct 97; 11 Jan 00. Integrin-linked kinase and its uses. Dedhar; Shoukat, et al. 536/23.1; 435/320.1 435/325 435/70.1. C07H021/02 C12N015/00 C12P021/04.
- ☐ 13. 6001622. 05 Mar 98; 14 Dec 99. Integrin-linked kinase and its use. Dedhar; Shoukat, et al. 435/194; 435/15. C12N009/12 C12Q001/48.


[Generate Collection](#)[Print](#)

Terms	Documents
human near4 ilk	13

[Previous Page](#)[Next Page](#)

=> d his

(FILE 'HOME' ENTERED AT 14:20:41 ON 28 MAY 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH' ENTERED AT 14:20:56 ON 28 MAY 2003

L1 20 S HUMAN(3A) INTEGRIN-LINKED(W) KINASE
L2 4 S (DNA OR CDNA OR POLYNUCLEOTIDE OR NUCLEIC(W)ACID OR NUCLEOTID
L3 4 DUP REM L2 (0 DUPLICATES REMOVED)

=> d bib ab 1-4 l3

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 2002:814830 CAPLUS
DN 137:321374
TI Use of integrin-linked kinase associated protein in regulation of
angiogenesis
IN Lorens, James B.; Xu, Weiduan; Atchison, Robert E.; Bogenberger, Jakob
PA Rigel Pharmaceuticals, Inc., USA
SO U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002156003	A1	20021024	US 2001-935124	20010821
	WO 2002085289	A2	20021031	WO 2002-US12341	20020418
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2001-284760P	P	20010418		
	US 2001-935124	A	20010821		

AB The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding C1-angiogenesis protein, also called integrin-linked kinase-assocd. serine/threonine phosphatase 2C ("ILKAP") and ILKAP protein, which is involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small org. mols., antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, and ribozymes, that modulate angiogenesis via modulation of ILKAP and ILKAP-related cascades; as well as to the use of expression profiles and compns. in diagnosis and therapy of angiogenesis.

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 2001:397060 CAPLUS
DN 135:15150
TI **Human integrin-linked kinase ILK-2**
and **cdNA** and methods of diagnosing and treating cancer
metastases
IN Kieffer, Nelly; Melchior, Chantal; Janji, Bassam
PA Centre National De La Recherche Scientifique (CNRS), Fr.; Centre De
Recherche Public De La Sante-CRP-Sante
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001038542	A1	20010531	WO 2000-FR3247	20001122
	W: AU, CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				

FR 2801318	A1	20010525	FR 1999-14711	19991123
------------	----	----------	---------------	----------

PRAI FR 1999-14711 A 19991123

AB The invention concerns an isoform of human integrin-linked kinase, called ILK-2, which is overexpressed in cancer cells with high invasive potential. The invention concerns a method for detecting and/or quantifying ILK-2 in a biol. sample by RFLP. Another aspect of the invention concerns a method for screening compds. capable of inhibiting ILK-2, and the use of said compds. for treating various pathologies, in particular in cancer for avoiding and/or preventing metastases.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS

AN 2001:437535 CAPLUS

DN 135:191804

TI A novel integrin-linked kinase-binding protein, affixin, is involved in the early stage of cell-substrate interaction

AU Yamaji, Satoshi; Suzuki, Atsushi; Sugiyama, Yuki; Koide, Yu-Ichi; Yoshida, Michihiko; Kanamori, Heiwa; Mohri, Hiroshi; Ohno, Shigeo; Ishigatsubo, Yoshiaki

CS The First Department of Internal Medicine, Yokohama City University School of Medicine, Yokohama, 236-0004, Japan

SO Journal of Cell Biology (2001), 153(6), 1251-1264

CODEN: JCLBA3; ISSN: 0021-9525

PB Rockefeller University Press

DT Journal

LA English

AB Focal adhesions (FAs) are essential structures for cell adhesion, migration, and morphogenesis. Integrin-linked kinase (ILK), which is capable of interacting with the cytoplasmic domain of .beta.1 integrin, seems to be a key component of FAs, but its exact role in cell-substrate interaction remains to be clarified. Here, we identified a novel ILK-binding protein, affixin, that consists of two tandem calponin homol. domains. In CHO cells, affixin and ILK co-localize at FAs and at the tip of the leading edge, whereas in skeletal muscle cells they co-localize at the sarcolemma where cells attach to the basal lamina, showing a striped pattern corresponding to cytoplasmic Z-band striation. When CHO cells are re-plated on fibronectin, affixin and ILK but not FA kinase and vinculin conc. at the cell surface in blebs during the early stages of cell spreading, which will grow into membrane ruffles on lamellipoda. Over-expression of the C-terminal region of affixin, which is phosphorylated by ILK in vitro, blocks cell spreading at the initial stage, presumably by interfering with the formation of FAs and stress fibers. The co-expression of ILK enhances this effect. These results provide evidence suggesting that affixin is involved in integrin-ILK signaling required for the establishment of cell-substrate adhesion.

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS

AN 1997:506614 CAPLUS

DN 127:119992

TI Cloning of **cdNA for human integrin-linked kinase**, its inhibitors, and their clinical applications

IN Dedhar, Shoukat; Hannigan, Greg

PA Dedhar, Shoukat, Can.; Hannigan, Greg
 SO PCT Int. Appl., 62 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9723625	A1	19970703	WO 1996-CA760	19961119
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2239151	AA	19970703	CA 1996-2239151	19961119
	AU 9676146	A1	19970717	AU 1996-76146	19961119
	AU 717466	B2	20000330		
	EP 870033	A1	19981014	EP 1996-938869	19961119
	R: AT, BE, CH, DE, DK, FR, GB, LI, NL, SE, MC, PT, IE, FI				
	NZ 322401	A	20000228	NZ 1996-322401	19961119
	JP 2001515344	T2	20010918	JP 1997-523163	19961119
PRAI	US 1995-9074P	P	19951221		
	WO 1996-CA760	W	19961119		
AB	Disclosed is an isolated and purified serine/threonine kinase which is an integrin-linked kinase, designated "ILK". ILK can be used to modulate cell growth, cell adhesion, cell migration, and cell invasion. ILK-inhibiting mols. are clin. useful for treating the diseases such as cancer, leukemia, chronic inflammatory disease, arthritis, osteoporosis and cardiovascular disease. Diagnostics contg. nucleotides derived from the ILK-encoding cDNA, the serine/threonine kinase, or its inhibitors are claimed.				

=>